Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

Exclusion Criteria

• •1. Previous received or planned to be vaccinated with 2019-nCoV vaccine or other vaccines within 3 months prior to the start of study treatment or during the study or within 3 months after the end of the study;
• •2. Previous radiotherapy within 4 weeks prior to the start of study treatment. (if palliative radiotherapy was given to bone metastatic side peripherally and the patient recovered from acute toxicity was allowed).
• •3. Previous anti-tumor therapy within 4 weeks prior to the start of study treatment.
• •4. Previous major operation within 8 weeks prior to the start of study treatment.
• •5. Prior severe allergic reaction or intolerance to a monoclonal antibody, including humanised or chimeric antibodies.
• •6. Symptomatic cerebral metastases.
• •7. Uncontrolled or severe illness.
• •8. Known human immunodeficiency virus infection or known symptomatic hepatitis
• •9. Other clinically significant disease which may have adversely affected the safe delivery of treatment within this study